"Hyperglycemia aversiveness": Investigating an overlooked problem among adults with type 1 diabetes
- PMID: 33836966
- DOI: 10.1016/j.jdiacomp.2021.107925
"Hyperglycemia aversiveness": Investigating an overlooked problem among adults with type 1 diabetes
Abstract
Aims: To investigate the problem of adults with type 1 diabetes (T1D) who purposefully keep their glucose levels low, and to explore contributors to, and possible impact of, this potentially dangerous phenomenon.
Methods: We developed three self-report items as a means to identify individuals who endorse a consistent preference for hypoglycemia over hyperglycemia ("Hyperglycemia Aversives"). In a large T1D survey (n = 219), validated measures of well-being, emotional distress and hypoglycemic awareness, and glycemic metrics derived from the past 14-day period, were used to examine whether Hyperglycemia Aversives could be characterized as a distinct group.
Results: Hyperglycemia Aversives comprised 16.4% of the sample. This unique group demonstrated significantly higher mean %TIR (71.6% vs. 63.6%) and %TBR (5.1% vs. 2.2%), lower mean %TAR > 250 mg/dL (6.0% vs. 10.1%), and higher rates of impaired hypoglycemic awareness and recurrent severe hypoglycemia episodes than the remaining study sample ("Non-Aversives") (all ps < 0.01). The two groups did not demonstrate significant differences on psychosocial outcomes.
Conclusions: We identified a group of T1D adults reporting a consistent preference for hypoglycemia over hyperglycemia. These individuals achieve significantly greater %TIR and less %TAR, but at the cost of greater %TBR and more frequent severe hypoglycemia episodes.
Keywords: Fear; Hyperglycemia; Hypoglycemia; Preference; Type 1 diabetes.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest No author reported a conflict of interest. William Polonsky: consultant for Dexcom, Onduo, Adocia, Insulet, Boehringer Ingelheim, Intuity, Novo Nordisk, Lilly Diabetes, Astra Zeneca, Sanofi Diabetes, Roche Diabetes, Abbott Diabetes, Xeris Pharmaceuticals, and Johnson & Johnson. AF reports no competing interests. DP is an employee and shareholder of Dexcom. LF: consultant for Eli Lilly, Abbott Diabetes Care and Sanofi Diabetes Care.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous